Bayer Falls Short in Bid to Beat Eliquis in Afib, But Key Stroke Study Continues
An independent data monitoring committee concluded Bayer’s experimental drug for atrial fibrillation would not be more effective than Eliquis, a blockbuster product currently used for the indication. Consequently, Bayer decided to stop that Phase 3 test for the once-daily oral small molecule.
United States Christian Rommel William Blair Matt Phipps Bristol Myers Squibb Bayer Pharmaceutical Division
Source: medcitynews.com